A Phase 3 Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Urinary Bladder
    Bladder Cancer
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Recurrent low-grade Ta (LG Ta) within 12 months of prior low-grade or highgrade (high-grade Ta [HG Ta] =3 cm) tumor
    2. Has had all visible disease removed by TURBT at baseline within 12 weeks of study randomization, prior to study treatment or initiation of observation period
    3. Is willing to comply with study-mandated cystoscopies, urine cytology, CT urogram, TURBTs/biopsies, and other procedures

You may not be eligible for this study if the following are true:

    1. Has disease that cannot be completely resected
    2. Has current or history of muscle-invasive (T2 or higher stage) bladder cancer or locally advanced (T3/T4, any N) or metastatic bladder cancer
    3. Has history of high-grade or low-grade urothelial carc



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.